Transaction · 0001193125-26-418101

KASINGER JAMES R.

KASINGER JAMES R., GC, SECY, reported an open-market or private sale at CRISPR Therapeutics AG involving 1990.000000 shares for an estimated $119481.19. Reported holdings after the transaction were 94784.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SGC, SECY
CRSPCRISPR Therapeutics AG
Filing timeOct 08
Trade dateOct 06, 2026
Filing · SECView on SEC
InsiderProfile
% of reported position traded2.06%Shares sold ÷ (holdings after + shares sold). Estimated position before: 96,774 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$50.44
Pre-filing
1mo ago1w ago +11.0%1d ago +13.7%
Returns since
7d30d90d180d1y

CRSP price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
CRSP since 2026-10-08Filed yesterday · 1 day of post-filing data
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001193125-26-418101
Common Shares
Transaction date
Oct 06, 2026
Filed Oct 08, 2026, 09:35 PM · 2d delay
Shares
1.99k sh
$60.04 per share
Estimated value
-$119k
Computed from shares × price
Holdings after
94.7k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership Repeat Seller 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

General Counsel and Secretary

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2026.

  2. F2

    The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.08, inclusive. The reporting person undertakes to provi…

  3. F3

    This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months.

Original filing · 0001193125-26-418101
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

CRSP